Literature DB >> 20005516

Lipoprotein-associated phospholipase A(2), inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).

Muriel J Caslake1, Chris J Packard, Michele Robertson, Josephine Cooney, Jeanenne J Nelson, Ian Ford, Allan Gaw, J Wouter Jukema, Peter W Macfarlane, David J Stott, James Shepherd.   

Abstract

OBJECTIVE: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an inflammatory biomarker that circulates mainly bound to LDL. We evaluated the association of Lp-PLA(2) with vascular events in the elderly where the importance of LDL is diminished as a risk factor for coronary disease.
METHODS: Mass and activity of Lp-PLA(2) were related to risk over 3.2 years for vascular events (definite or suspected death from CHD, non-fatal MI, fatal or non-fatal stroke) in the 2804 men and 3000 women age 70-82 years in the Prospective Study of Pravastatin in the Elderly (PROSPER).
RESULTS: Lp-PLA(2) showed a moderate, positive association with risk of a vascular event with hazard ratios of 1.25 (confidence interval (CI) 1.02-1.54) for mass and 1.39 (CI 1.14-1.70) for activity for top versus bottom quartile. Risk associations were attenuated when classical risk factors, lipids and inflammatory markers - C-reactive protein and white cell count - were included in the models. Lp-PLA(2) was unrelated to stroke risk. Inclusion of all three inflammatory markers in multivariate models negated the association of HDL cholesterol with risk (hazard ratio 0.98; CI 0.88-1.10) and increased prediction of coronary events; the C statistic rose from 63.2% to 64.4% (P<0.001).
CONCLUSION: In elderly people Lp-PLA(2), alongside other inflammatory indices, is a potential biomarker for vascular events, particularly CHD. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20005516     DOI: 10.1016/j.atherosclerosis.2009.10.041

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

1.  Lp-PLA2: inflammatory biomarker of vascular risk in multiple sclerosis.

Authors:  Zohara Sternberg; Alison Drake; Daniel S Sternberg; Ralph H B Benedict; Fan Li; David Hojnacki; Bianca Weinstock-Guttmann; Frederick E Munschauer
Journal:  J Clin Immunol       Date:  2012-01-13       Impact factor: 8.317

Review 2.  Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction.

Authors:  Thomas J Wang
Journal:  Circulation       Date:  2011-02-08       Impact factor: 29.690

3.  Clinical utility of lipoprotein-associated phospholipase A₂ for cardiovascular disease prediction in a multiethnic cohort of women.

Authors:  Nancy R Cook; Nina P Paynter; Joann E Manson; Lisa W Martin; Jennifer G Robinson; Sylvia Wassertheil-Smoller; Paul M Ridker
Journal:  Clin Chem       Date:  2012-08-02       Impact factor: 8.327

4.  Normal levels of inflammatory markers in treated patients with familial hypercholesterolaemia: a cross-sectional study.

Authors:  Mary Seed; D John Betteridge; Jackie Cooper; Muriel Caslake; Paul N Durrington; Gilbert R Thompson; Naveed Sattar; Steve E Humphries; H Andrew W Neil
Journal:  JRSM Cardiovasc Dis       Date:  2012-06-30

5.  Lipoprotein-associated phospholipase A₂ is related to plaque stability and is a potential biomarker for acute coronary syndrome.

Authors:  Hyemoon Chung; Hyuck Moon Kwon; Jong-Youn Kim; Young-Won Yoon; Jihyuk Rhee; Eui-Young Choi; Pil-Ki Min; Bum-Kee Hong; Se-Joong Rim; Ji Hyun Yoon; Sung-Joo Lee; Jong-Kwan Park; Myung-Hyun Kim; Minhee Jo; Jeong-Hee Yang; Byoung Kwon Lee
Journal:  Yonsei Med J       Date:  2014-11       Impact factor: 2.759

6.  The effect of hepatitis C virologic clearance on cardiovascular disease biomarkers in human immunodeficiency virus/hepatitis C virus coinfection.

Authors:  Kara W Chew; Lei Hua; Debika Bhattacharya; Adeel A Butt; Lorelei Bornfleth; Raymond T Chung; Janet W Andersen; Judith S Currier
Journal:  Open Forum Infect Dis       Date:  2014-12-03       Impact factor: 3.835

7.  Lipoprotein-Associated Phospholipase A2 Activity and Mass as Independent Risk Factor of Stroke: A Meta-Analysis.

Authors:  Gaifeng Hu; Deping Liu; Huiyu Tong; Weijun Huang; Yunzhao Hu; Yuli Huang
Journal:  Biomed Res Int       Date:  2019-05-20       Impact factor: 3.411

Review 8.  Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles.

Authors:  John M Gregson; Daniel F Freitag; Praveen Surendran; Nathan O Stitziel; Rajiv Chowdhury; Stephen Burgess; Stephen Kaptoge; Pei Gao; James R Staley; Peter Willeit; Sune F Nielsen; Muriel Caslake; Stella Trompet; Linda M Polfus; Kari Kuulasmaa; Jukka Kontto; Markus Perola; Stefan Blankenberg; Giovanni Veronesi; Francesco Gianfagna; Satu Männistö; Akinori Kimura; Honghuang Lin; Dermot F Reilly; Mathias Gorski; Vladan Mijatovic; Patricia B Munroe; Georg B Ehret; Alex Thompson; Maria Uria-Nickelsen; Anders Malarstig; Abbas Dehghan; Thomas F Vogt; Taishi Sasaoka; Fumihiko Takeuchi; Norihiro Kato; Yoshiji Yamada; Frank Kee; Martina Müller-Nurasyid; Jean Ferrières; Dominique Arveiler; Philippe Amouyel; Veikko Salomaa; Eric Boerwinkle; Simon G Thompson; Ian Ford; J Wouter Jukema; Naveed Sattar; Chris J Packard; Abdulla Al Shafi Majumder; Dewan S Alam; Panos Deloukas; Heribert Schunkert; Nilesh J Samani; Sekar Kathiresan; Børge G Nordestgaard; Danish Saleheen; Joanna Mm Howson; Emanuele Di Angelantonio; Adam S Butterworth; John Danesh
Journal:  Eur J Prev Cardiol       Date:  2016-12-08       Impact factor: 7.804

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.